guanidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1344 | 113-00-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 592.51 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 2, 1939 | FDA | MERCK SHARP DOHME |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Radiation inflammation | 123.21 | 116.24 | 19 | 403 | 886 | 34955623 |
| Pulmonary pain | 117.47 | 116.24 | 19 | 403 | 1205 | 34955304 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pulmonary pain | 266.99 | 150.51 | 44 | 647 | 4429 | 79739268 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| FDA PE | N0000009079 | Increased Acetylcholine Activity |
| FDA EPC | N0000175772 | Acetylcholine Releasing Agent |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Eaton-Lambert syndrome | indication | 56989000 | DOID:0050214 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.39 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Voltage-gated potassium channel | Ion channel | BLOCKER | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| JU58VJ6Y3B | UNII |
| 4019772 | VUID |
| N0000147863 | NUI |
| 50-01-1 | SECONDARY_CAS_RN |
| 4018993 | VANDF |
| 4019772 | VANDF |
| C0120446 | UMLSCUI |
| CHEBI:42820 | CHEBI |
| GAI | PDB_CHEM_ID |
| CHEMBL821 | ChEMBL_ID |
| 3520 | PUBCHEM_CID |
| DB00536 | DRUGBANK_ID |
| CHEMBL1200728 | ChEMBL_ID |
| D019791 | MESH_DESCRIPTOR_UI |
| 4783 | IUPHAR_LIGAND_ID |
| 50675 | RXNORM |
| 4810 | MMSL |
| 530 | MMSL |
| 72830 | MMSL |
| d01422 | MMSL |
| 001698 | NDDF |
| 004685 | NDDF |
| 109108004 | SNOMEDCT_US |
| 409368007 | SNOMEDCT_US |
| 412195000 | SNOMEDCT_US |
Pharmaceutical products:
None